Cochrane · systematic review · CD010638
Oral and sublingual immunotherapy for egg allergy
Romantsik, O, Tosca, MA, Zappettini, S, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyOral and sublingual immunotherapy versus no therapy for egg allergy
Population: children with egg allergy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Increase in the amount of egg that could be tolerated Oral and sublingual immunotherapy vs no therapy | RR 7.48 [4.91, 11.38] | 9 studies · 410 participants | Low Downgraded: risk of bias, imprecision |
Complete recovery Oral and sublingual immunotherapy vs no therapy | RR 4.25 [2.77, 6.53] | 10 studies · 439 participants | Low Downgraded: risk of bias, imprecision |
Numbers of children with serious adverse events Oral and sublingual immunotherapy vs no therapy | no estimate extracted | 10 studies · 439 participants | Low Downgraded: risk of bias, imprecision |
Number of children with mild‐to‐severe adverse events Oral and sublingual immunotherapy vs no therapy | RR 8.35 [5.31, 13.12] | 10 studies · 439 participants | Low Downgraded: risk of bias, imprecision |
Oral and sublingual immunotherapy compared to no therapy for egg allergy
Population: patients with egg allergy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
increase in the amount of egg that can be tolerated Oral and sublingual immunotherapy vs no therapy | RR 5.73 [3.13, 10.5] | 4 studies · 167 participants | Low Downgraded: risk of bias, imprecision |
complete recovery Oral and sublingual immunotherapy vs no therapy | RR 3.39 [1.74, 6.62] | 4 studies · 167 participants | Low Downgraded: risk of bias, imprecision |
serious adverse events Oral and sublingual immunotherapy vs no therapy | no estimate extracted | 4 studies · 167 participants | Low Downgraded: risk of bias, imprecision |
mild to severe adverse reactions Oral and sublingual immunotherapy vs no therapy | RR 6.06 [3.11, 11.83] | 4 studies · 167 participants | Low Downgraded: risk of bias, imprecision |